Adicet Bio (NASDAQ:ACET) Stock

Adicet Bio

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

analyst ratings image

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

ACET

ANIP

RLAY

SUPN

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

IN8bio’s Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data 

Biotech

Penny Stocks

General

INAB

IPSC

IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors.

IN8bio&#39;s Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data

Small Cap

Intraday Update

Movers

ACCD

ACMR

AIMD

BETS

BOWL

CENX

CUTR

DECA

GOEV

GRFS

GRTX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

ILMN

JBLU

JNPR

JWEL

KITT

KORE

LDTC

Morgan Stanley Capital Protected Notes for S&P 500 Index

NEOG

NEXI

SNTG

TCJH

TLRY

URBN

VIRI

YCBD

ZCAR

PTHR

Shares of JetBlue Airways Corporation (NASDAQ: JBLU) fell sharply during Tuesday’s session.

Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Adicet Bio Inc

JMP Securities analyst Reni Benjamin reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Market Perform to Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on Adicet Bioto Market Perform

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Neutral to Neutral.

HC Wainwright & Co. Reiterates Neutral on Adicet Bioto Neutral

WIIM

Adicet Bio shares are trading higher after the company was granted FDA Fast Track designation to ADI-001 for treating refractory systemic lupus erythematosus with extrarenal involvement.

Adicet Bio Secures FDA Fast Track Status For ADI-001 In Treating Refractory Systemic Lupus Erythematosus (SLE) With Extrarenal Involvement

Adicet Bio Says FDA Granted Fast Track Designation To ADI-001 For Potential Treatment Of Adult Patients With Refractory Systemic Lupus Erythematosus With Extrarenal Involvement

Plans To Advance Phase 1 Trial Of ADI-001 Across Six Autoimmune Diseases With Preliminary Lupus Nephritis Data Expected In 1H25 And Additional Cohort Data In 2H25; Enrollment For SLE, SSc, IIM, And SPS To Begin In Q1 2025, AAV Enrollment Expected In 2H25; Reports First Patient Dosed In ADI-270 Phase 1 Trial For Metastatic ccRCC With Preliminary Data Anticipated In 1H25; Company Positioned To Build On Momentum In Autoimmune And On

Adicet Bio Highlights Key 2025 Milestones Following 2024 Progress

Adicet Bio Says First Patient Dosed In The Phase 1 Clinical Trial Evaluating ADI-270 In Patients With Metastatic/Advanced ccRCC

First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials
Preliminary Phase 1 clinical data expected in the first half of 2025
Adicet Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).

Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical Data Expected In The First Half Of 2025

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Neutral.

HC Wainwright & Co. Reiterates Neutral on Adicet Bio

-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue
-Results highlight the potential benefits unique to gamma delta 1 CAR T cell therapy and ADI-001's potential as a best-in-class off-the-shelf cell therapy for autoimmune diseases
-The company is pursuing ADI-001 in a basket study across six indications including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV)

Reported Saturday, Adicet Bio Shared Clinical Biomarker Data On Off-The-Shelf CAR T Cell Therapy During Oral Session At ACR Convergence 2024

Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 52.11 percent increase over losses of $(0.71) per share from the same period last year.

Earnings

Earnings Beats

Adicet Bio Q3 EPS $(0.34) Beats $(0.35) Estimate

Adicet Bio shares are trading higher after the company announced FDA clearance of an IND amendment to evaluate ADI-001 in idiopathic inflammatory myopathy and stiff person syndrome.

Adicet Bio Announces FDA Clearance Of An IND Amendment To Evaluate ADI-001 In Idiopathic Inflammatory Myopathy And Stiff Person Syndrome

Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Outperform and maintains $5 price target.

Price Target

Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target

ADI-001 demonstrated robust tissue trafficking resulting in high levels of ADI-001, significant chimeric antigen receptor (CAR) T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue.&nbsp;

Health Care

Adicet Bio Announced ADI-001 Clinical Biomarker Data From The Phase 1 GLEAN Trial Which Further Reinforces The Potential Of ADI-001 As Allogeneic Cell Therapy For Autoimmune Diseases

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02a43eaaa00018d939e/edward-white">HC Wainwright &amp; Co. analyst Edward White</a> downgraded the rating for Adicet Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Buy to Neutral. Adicet Bio shares fell 3.4% to close at $1.43 on Tuesday. <a href="https://www.benzinga.com/quote/DACETPZ/analyst-ratings">See how other analysts </a><a href="https://www.benzinga.com/quote/ACET/analyst-ratings">view </a><a href="https://www.benzinga.com/quote/DACETPZ/analyst-ratings">this stock</a>.</li>
<li>B of A Securities analyst Graham Perry downgraded Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral and lowered the price target from $135 to $130. Novartis shares fell 0.2% to close at $116.99 on Tuesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/topic/david-amsellem">Piper Sandler analyst David Amsellem</a> downgraded the rating for Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and cut the price target from $41 to $36. Supernus Pharmaceuticals shares fell 1.2% to close at $33.49 on Tuesday. <a href="https://www.benzinga.com/quote/SUPN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Gregory Fraser downgraded ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) from Buy to Hold and slashed the price target from $80 to $60. ANI Pharmaceuticals shares fell 5.1% to close at $55.48 on Tuesday. <a href="https://www.benzinga.com/quote/ANIP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NVS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="537" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-1024x537.png" alt="" class="wp-image-542353" style="width:625px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-1024x537.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88.png 1292w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:<a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock">Jim Cramer Says AES Is &#8216;Very Inexpensive&#8217;, Recommends Buying This Industrial Stock</a></li>
</ul>

Press Releases

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Comments

Adicet Bio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga